BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia

Yulin Li; Anja Deutzmann; Peter S. Choi; Alice C. Fan; Dean W. Felsher

doi:10.18632/oncotarget.8731

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Priority Research Papers:

BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia

Yulin Li, Anja Deutzmann, Peter S. Choi, Alice C. Fan and Dean W. Felsher _

Oncotarget. 2016; 7:26926-26934. https://doi.org/10.18632/oncotarget.8731

Metrics: PDF 2108 views | HTML 16087 views | ?

Abstract

Yulin Li1, Anja Deutzmann1, Peter S. Choi1, Alice C. Fan1 and Dean W. Felsher1

1 Division of Oncology, Department of Medicine and Pathology, Stanford University, Stanford, CA, United States of America

Correspondence to:

Dean W. Felsher, email:

Keywords: apoptosis, BIM, targeted therapies, oncogene inactivation

Received: March 18, 2016 Accepted: April 08, 2016 Published: April 14, 2016

Abstract

Oncogene inactivation in both clinical targeted therapies and conditional transgenic mouse cancer models can induce significant tumor regression associated with the robust induction of apoptosis. Here we report that in MYC-, RAS-, and BCR-ABL-induced acute lymphoblastic leukemia (ALL), apoptosis upon oncogene inactivation is mediated by the same pro-apoptotic protein, BIM. The induction of BIMin the MYC- and RAS-driven leukemia is mediated by the downregulation of miR-17-92. Overexpression of miR-17-92 blocked the induction of apoptosis upon oncogene inactivation in the MYC and RAS-driven but not in the BCR-ABL-driven ALL leukemia. Hence, our results provide novel insight into the mechanism of apoptosis upon oncogene inactivation and suggest that induction of BIM-mediated apoptosis may be an important therapeutic approach for ALL.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8731

Publication Alerts

Priority Research Papers:

BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia

Abstract